Chemotherapy Induced Peripheral Neuropathy Drug Pipeline Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type
June 26, 2024 09:26 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.An insightful report...
Middle East & Africa Antibody Drug Conjugates Market Forecast to 2030 - Growing Strategic Partnerships to Develop Antibody Drug Conjugates and Escalating Pipeline of ADCs
June 26, 2024 04:23 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Middle East & Africa Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel"...
Chemotherapy Induced Nausea and Vomiting Drug Pipeline Research 2024 Featuring Helsinn Healthcare, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios, and Zhuhai Beihai Biotech
June 24, 2024 09:47 ET
|
Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
Comprehensive Insights of Global Cyclin-Dependent Kinase Inhibitor Pipeline
June 18, 2024 10:17 ET
|
Research and Markets
Dublin, June 18, 2024 (GLOBE NEWSWIRE) -- The "Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The detailed report furnishes...
CAR-T Therapy Pipeline Landscape Report, 2024 - Features Insights on Emerging Drugs CT053, Descartes-08, ALLO-501A, CTX110, and IMPT 314
June 14, 2024 06:23 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This report provides in-depth insights into the...
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
June 13, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the...
Chemotherapy-Induced Anemia Pipeline Insights Report, 2024 Featuring Analysis of Roxadustat (FibroGen), SPP-003 (SBI Pharmaceuticals), and More
May 31, 2024 06:26 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Anemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
Global Pharmaceutical Industry Outlook 2024: Key Growth Opportunities in Scaling Precision Oncology in Asia-Pacific Through Public-private Partnership Models
May 27, 2024 04:33 ET
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical Industry Outlook, 2024" report has been added to ResearchAndMarkets.com's offering.The leading trends shaping the global...
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
May 02, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
April 29, 2024 07:59 ET
|
Pasithea
Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.